Tokai Pharmaceuticals to Present at the 15th Annual Needham Healthcare Conference

BOSTON–(BUSINESS WIRE)– Tokai Pharmaceuticals Inc. (NASDAQ:TKAI), a biopharmaceutical company
focused on developing and commercializing innovative therapies for
prostate cancer and other hormonally driven diseases, today announced
that management will present at the 15^th Annual Needham
Healthcare Conference on Wednesday, April 13, 2016 at 1:40pm ET at The
Westin Grand Central in New York City.

A live webcast of the presentation can be accessed under the “Calendar
of Events” page within the Investors & Media section of the company’s
website at www.tokaipharma.com.
A replay of the webcast will be archived on the Tokai website for 90
days following the date of the presentation.

About Tokai Pharmaceuticals

Tokai Pharmaceuticals is a biopharmaceutical company focused on
developing and commercializing innovative therapies for prostate cancer
and other hormonally driven diseases. The company’s lead drug candidate,
galeterone, is an oral small molecule that utilizes the mechanistic
pathways of current second-generation anti-androgens, while also
introducing a unique third mechanism – androgen receptor
degradation. Tokai is developing galeterone for the treatment of
patients with metastatic castration-resistant prostate cancer. The
company’s ARDA drug discovery program is focused on the identification
and evaluation of compounds that are designed to disrupt androgen
receptor signaling through enhanced androgen receptor degradation and
are targeted to patients with androgen receptor signaling diseases,
including prostate cancer. For more information on the company and
galeterone, please visit www.tokaipharma.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160406005003/en/